USAID, Janssen Therapeutics Sign MOU To Support Efforts To Address MDR-TB

IIP Digital: More Nations to Receive Tuberculosis-Fighting Drug
“The U.S. Agency for International Development (USAID) signed a memorandum of understanding (MOU) with Janssen Therapeutics December 11 that aims to accelerate progress in the fight against antibiotic-resistant bacteria, specifically multidrug-resistant tuberculosis (MDR-TB). The intent of the MOU is for Janssen to donate $30 million worth of the drug SIRTURO® (bedaquiline) over a four-year period through USAID’s programs for the treatment of MDR-TB…” (12/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.